ANIPANI PHARMACEUTICALS INC同业对比
ANI PHARMACEUTICALS INC 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANIP本股 | — | 16.1x#3 | — | — | 43.8%#7 | 510.5%#2 | 12.6%#3 | 13.1%#2 | 16.9%#1 | — | -24.5%#12 | — |
| AGIO | $2.0B#1 | — | 1.9x#4 | 36.4x#9 | 48.0%#6 | -161.3%#11 | -873.9%#11 | -40.3%#10 | — | — | -10.2%#10 | — |
| PRGO | $1.9B#2 | — | 0.7x#1 | 0.4x#1 | -2.8%#11 | -729.7%#12 | -26.4%#6 | -56.7%#12 | -20.9%#4 | 4#2 | -31.2%#13 | 8.5%#1 |
| ZYME | $1.9B#3 | — | 23.1x#11 | 17.6x#7 | 38.9%#8 | 33.9%#6 | -87.3%#7 | -100.9%#13 | — | — | 65.5%#6 | — |
| BHVN | $1.8B#4 | — | 148.4x#15 | — | — | 12.7%#8 | — | -6045.0%#16 | — | — | -10.9%#11 | — |
| STOK | $1.8B#5 | — | 5.2x#10 | 9.8x#5 | 404.5%#3 | 92.3%#3 | -11.2%#5 | -2.0%#6 | — | — | 20.6%#7 | — |
| SEPN | $1.8B#6 | — | 4.6x#9 | 39.0x#10 | 4174.5%#1 | 31.9%#7 | -148.6%#9 | -12.6%#8 | — | — | 165.5%#5 | — |
| XNCR | $1.8B#7 | — | 3.5x#7 | 14.0x#6 | 13.7%#10 | 60.5%#5 | -141.4%#8 | -18.3%#9 | -31.5%#5 | — | 174.9%#4 | — |
| KLRA | $1.6B#8 | — | 1.5x#3 | — | — | — | — | 0.0%#3 | — | — | — | — |
| KARD | $1.6B#9 | — | 2.6x#5 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ETON | $1.6B#10 | — | 34.6x#12 | 20.1x#8 | 104.9%#5 | -20.4%#10 | -1.1%#4 | -9.9%#7 | -1.8%#3 | 4#2 | 220.3%#2 | — |
| ANAB | $1.6B#11 | — | 124.0x#14 | 6.7x#3 | 157.0%#4 | 90.9%#4 | 20.4%#2 | -103.8%#14 | — | — | 180.0%#3 | — |
| SNDX | $1.5B#12 | — | 102.1x#13 | 8.9x#4 | 627.8%#2 | 10.5%#9 | -158.4%#10 | -1890.2%#15 | -1205.8%#6 | — | 14.9%#8 | — |
| AVLN | $1.5B#13 | — | 3.9x#8 | — | — | — | — | 0.0%#3 | — | — | — | — |
| INVA | $1.5B#14 | 4.9x#2 | 1.2x#2 | 3.7x#2 | 14.7%#9 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#2 | 5#1 | 9.8%#9 | — |
| DMRA | $1.5B#15 | 3.2x#1 | 2.9x#6 | — | — | -878.8%#13 | — | -40.7%#11 | — | — | 751.8%#1 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议